Reuters logo
BRIEF-Checkpoint Therapeutics initiates phase 1 study of antibody CK-301 for metastatic cancers
October 5, 2017 / 11:33 AM / 2 months ago

BRIEF-Checkpoint Therapeutics initiates phase 1 study of antibody CK-301 for metastatic cancers

Oct 5 (Reuters) - Checkpoint Therapeutics Inc:

* Checkpoint Therapeutics initiates phase 1 study of anti-PD-L1 antibody CK-301

* Checkpoint Therapeutics Inc - ‍look forward to providing clinical updates on phase 1 study in first half of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below